Letters Cancer drugs and copayments

Critical issue is rapidity of review of new drugs

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a779 (Published 14 July 2008) Cite this as: BMJ 2008;337:a779
  1. Alan Rodger, medical director
  1. 1Beatson West of Scotland Cancer Centre, Glasgow G12 0YN
  1. alan.rodger{at}ggc.scot.nhs.uk

    Baroness Finlay and Lord Crisp support copayments with four essential criteria.1 The fourth criterion will fail as the denominator is described as a small group in the scale of the NHS’s customer base. There is also the assurance that this is “mostly” for drugs yet to be reviewed by the National Institute for Health and Clinical Excellence (NICE).

    That is not the experience revealed by recent high profile cases in the …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe